Page 62 - Approval Program News Today

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

BASEL (dpa-AFX) - Novartis (NVS) said that the U.S. Food and Drug Administration granted accelerated approval to Vijoice or alpelisib for the treatment of adult and pediatric patients 2 years of

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum...

Orange County Water District’s (OCWD; the District) Philip L. Anthony Water Quality Laboratory is the first public agency laboratory in...

This Week in Washington: Congress Passes Appropriations to Fund Government Through Fiscal Year 2023...

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data

Investegate announcements from NuCana plc, NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study